ARTICLE | Finance
Syncona eyes a matching pair
Why Syncona felt two gene therapy investments would fare better as one company
April 11, 2019 6:03 AM UTC
Ten months after rounding out its gene therapy strategy with the last two investments in a five-company portfolio, Syncona has decided that two of its companies will fare better as a single entity.
Syncona Ltd. (LSE:SYNC) has decided to merge Gyroscope Therapeutics Ltd. with Orbit Biomedical Ltd., which it says creates the first gene therapy company for retinal diseases that includes a clinical pipeline, an in-house manufacturing process and a delivery platform (see "Gene Therapies in Sync")...